Correlation
The correlation between AUPH and BMY is 0.40, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
AUPH vs. BMY
Compare and contrast key facts about Aurinia Pharmaceuticals Inc. (AUPH) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: AUPH or BMY.
Performance
AUPH vs. BMY - Performance Comparison
Loading data...
Key characteristics
AUPH:
1.06
BMY:
0.83
AUPH:
1.91
BMY:
1.38
AUPH:
1.21
BMY:
1.17
AUPH:
0.57
BMY:
0.53
AUPH:
3.18
BMY:
2.67
AUPH:
15.18%
BMY:
9.42%
AUPH:
43.56%
BMY:
31.39%
AUPH:
-87.58%
BMY:
-70.62%
AUPH:
-76.30%
BMY:
-33.83%
Fundamentals
AUPH:
$1.08B
BMY:
$98.25B
AUPH:
$0.27
BMY:
$2.70
AUPH:
29.59
BMY:
17.88
AUPH:
0.00
BMY:
2.26
AUPH:
4.37
BMY:
2.06
AUPH:
3.08
BMY:
5.60
AUPH:
$247.30M
BMY:
$47.64B
AUPH:
$218.23M
BMY:
$31.43B
AUPH:
$54.34M
BMY:
$16.18B
Returns By Period
The year-to-date returns for both stocks are quite close, with AUPH having a -12.69% return and BMY slightly lower at -12.76%. Over the past 10 years, AUPH has outperformed BMY with an annualized return of 8.43%, while BMY has yielded a comparatively lower 0.11% annualized return.
AUPH
-12.69%
-4.85%
-11.51%
45.72%
-11.42%
-13.15%
8.43%
BMY
-12.76%
-3.82%
-16.68%
25.85%
-10.29%
-0.59%
0.11%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
AUPH vs. BMY — Risk-Adjusted Performance Rank
AUPH
BMY
AUPH vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
AUPH vs. BMY - Dividend Comparison
AUPH has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 5.05%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AUPH Aurinia Pharmaceuticals Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 5.05% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
Drawdowns
AUPH vs. BMY - Drawdown Comparison
The maximum AUPH drawdown since its inception was -87.58%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for AUPH and BMY.
Loading data...
Volatility
AUPH vs. BMY - Volatility Comparison
The current volatility for Aurinia Pharmaceuticals Inc. (AUPH) is 7.96%, while Bristol-Myers Squibb Company (BMY) has a volatility of 11.13%. This indicates that AUPH experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
AUPH vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Aurinia Pharmaceuticals Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AUPH vs. BMY - Profitability Comparison
AUPH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Aurinia Pharmaceuticals Inc. reported a gross profit of 53.89M and revenue of 62.47M. Therefore, the gross margin over that period was 86.3%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a gross profit of 8.17B and revenue of 11.20B. Therefore, the gross margin over that period was 72.9%.
AUPH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Aurinia Pharmaceuticals Inc. reported an operating income of 21.85M and revenue of 62.47M, resulting in an operating margin of 35.0%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported an operating income of 3.52B and revenue of 11.20B, resulting in an operating margin of 31.4%.
AUPH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Aurinia Pharmaceuticals Inc. reported a net income of 23.34M and revenue of 62.47M, resulting in a net margin of 37.4%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Bristol-Myers Squibb Company reported a net income of 2.46B and revenue of 11.20B, resulting in a net margin of 21.9%.